Hikma Pharmaceuticals (OTCMKTS:HKMPF) Share Price Passes Above 50-Day Moving Average – Should You Sell?

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF)’s share price passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $19.99 and traded as high as $21.56. Hikma Pharmaceuticals shares last traded at $21.56, with a volume of 607 shares changing hands.

Wall Street Analyst Weigh In

Separately, Citigroup initiated coverage on Hikma Pharmaceuticals in a research report on Thursday, July 16th. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Hikma Pharmaceuticals currently has a consensus rating of “Hold”.

Hikma Pharmaceuticals Price Performance

The company has a current ratio of 1.82, a quick ratio of 1.06 and a debt-to-equity ratio of 0.57. The business’s 50-day simple moving average is $19.99 and its two-hundred day simple moving average is $19.42.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.